Berrino, P.M.; Gatti, M.; Rinaldi, M.; Brunocilla, E.; Viale, P.; Pea, F.
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections. Antibiotics 2023, 12, 1388.
https://doi.org/10.3390/antibiotics12091388
AMA Style
Berrino PM, Gatti M, Rinaldi M, Brunocilla E, Viale P, Pea F.
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections. Antibiotics. 2023; 12(9):1388.
https://doi.org/10.3390/antibiotics12091388
Chicago/Turabian Style
Berrino, Pasquale Maria, Milo Gatti, Matteo Rinaldi, Eugenio Brunocilla, Pierluigi Viale, and Federico Pea.
2023. "Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections" Antibiotics 12, no. 9: 1388.
https://doi.org/10.3390/antibiotics12091388
APA Style
Berrino, P. M., Gatti, M., Rinaldi, M., Brunocilla, E., Viale, P., & Pea, F.
(2023). Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections. Antibiotics, 12(9), 1388.
https://doi.org/10.3390/antibiotics12091388
